Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in Prostate Cancer
NCT02421575Phase 1Terminated
- Sponsor
- Rutgers University
- Start
- Jul 2012
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hydroxychloroquine in prostate carcinoma (3 arms), sponsored by Rutgers University. Primary endpoints: Change in markers of autophagy in prostate tumor and Levels of markers of autophagy in prostate tumor up to 1 year. Started Jul 2012; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
prostate carcinoma
Beyond the preview
Go deeper on NCT02421575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02421575.